更新日期:2021年7月7日

角色:急性呼吸道感染组

1.在过去三十六个月，你有否接受某商业机构就CRG的广泛主题范畴提供的下列资料?

a)支持参加会议，包括休假和游学(包括旅行、住宿和/或接待)?
没有

b)讲座、报告、报告局、手稿写作或教育活动的报酬或酬金?
没有

c)组织教育的费用?
没有

d)赠款和合同?
是的,TJ获得了Cochrane方法创新基金(Cochrane Methods Innovations Fund, 2015-018)的拨款，用于制定Cochrane综述中监管数据使用指南(2015-018)。2014年? ?2016年，TJ是Boehringer Ingelheim三个顾问委员会的成员。TJ是赛诺菲巴斯德流感疫苗临床试验独立数据监测委员会的成员。TJ偶尔会接受市场研究公司关于他收取费用的一期或二期药品的采访。TJ曾担任Boehringer Ingelheim的三个顾问委员会成员(2014-16)。TJ是一项代表美国的虚假声明法案诉讼的相关人员，该诉讼涉及为大规模流感储备而销售达菲。如果在美国解决??帮个忙，他将有权获得部分赔偿????。TJ是劳拉和约翰·阿诺德基金会(Laura and John Arnold Foundation)用于发展RIAT支持中心(2017-2020年)和让·莫内卫生法律和政策网络(2017-2020年)赠款的共同持有人。 TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022). TJ consults for Illumina LLC on next generation gene sequencing (2019-). TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019). Tom Jefferson competing interests statement 26 October 2019: TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018). In 2014???2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current). TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16) TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017). TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States??? favor, he would be entitled to a percentage of the recovery????. TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022). Tom Jefferson competing interests statement April 6, 2018: TJ was a corecipient of a UK National Institute for Health Research grant (HTA ??? 10/80/01 Update???and amalgamation of two Cochrane reviews: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children; https://www.journalslibrary.nihr.ac.uk/programmes/hta/108001/). TJ was also in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews. TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products. In 2011???2014, TJ acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada. He has acted as a consultant for Roche (1997???1999), GSK (2001???2002), Sanofi-Synthelabo (2003) and IMS Health (2013). In 2014???2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine. TJ has a potential financial conflict???of interest on the drug oseltamivir. TJ was a cosignatory of a complaint to the European Ombudsman on maladministration in relation to the EMA investigation of possible harms from HPV vaccines. TJ is co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ is an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022). TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.

e)员工的资金?
没有

f)咨询费用?
是的,见上图

g)版税或许可费?
是的,见上图

h)专家作证的报酬?
没有

i)奖学金的费用?
没有

j)参与数据安全监测委员会、咨询委员会或指南委员会的费用?
没有

k)在其他董事会、社会、委员会或倡导团体中担任领导或其他受托人角色的报酬?
没有

2.在过去36个月内，你、你的配偶/伴侣或直系亲属是否受雇于或拥有与CRG广泛的主题领域有经济利益关系的商业机构?
没有

3.你是否在CRG的广泛主题领域拥有商业组织的股票或股份?
没有

4.您是否拥有与CRG的广泛主题领域相关的产品的任何专利(计划中的、已发布的或正在申请的)?
没有

5.你有其他的竞争利益(财务或非财务)吗?
是的,参见https://restoringtrials.org/competing-interests-tom-jefferson/